/
DCF Valuation
Base-case fair value
$67.36
Intrinsic $89.82 · 25% MOS
Current price: $22.75
Base-case summary
Our base-case DCF for Pacira BioSciences, Inc. (PCRX) projects 10 years of free cash flow growth at 10.7% for years 1–5 and 5.4% for years 6–10, anchored to 10.7% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $133M in trailing free cash flow, this produces an intrinsic value of $89.82 per share. A 25% safety margin gives a fair value of $67.36, suggesting the stock is currently 196% undervalued against the $22.75 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$133M
Cash & equivalents
$202M
Total debt
$411M
Shares outstanding
41M